November 19, 2012
Many of us who live with HIV are alive today in part because we received effective treatment to clear our hepatitis C (HCV) co-infections. Interferon-boosted Ribavirin was a lifesaver, but the interferon side effects could be rugged.
MedPage Today reports that a triple-drug regimen without interferon has been found in a small study to be highly effective in clearing even treatment-resistant HCV genotype 1. FDA approval for clinical use is still a long way off, but we look forward to a future of effective HCV treatment without interferon.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Thank You, Paul Kawata: Reflections on USCA and Being a Gay Man of a Certain Age|